REXAHN PHARMACEUTICALS, INC. DEF 14A 6-6-2011

Company

Opus Genetics, Inc.

Filed

April 26, 2011

Period of Report

June 6, 2011

Accession Number

0001140361-11-023216

A DEF 14A is a proxy statement sent to shareholders before an annual meeting. It covers executive compensation, board elections, and shareholder votes. Learn more about DEF 14A filings →